Sanjay Shah, MD
Pediatric Hematology-Oncology · Mesa, AZNPI 1740263474
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,420 of the $10,625 with a category attached, or 88.7%. 7 manufacturers reported payments, led by Vertex at 46.6% of the total. Reporting peaked in 2022 at $4,979 and has fallen 99.3% since, to $34 in 2025.
Across 14 payments — averaging $758.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$5K
- Chiesi USA, Inc.$5K
- Agios Pharmaceuticals, Inc.$809
- Sobi, Inc$135
- Genetix Biotherapeutics Inc$54
- Novo Nordisk$42
- plus $16 from 1 others
Across 58 payments — averaging $4662.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Agios Pharmaceuticals, Inc.$122K
- Novartis$76K
- Global Blood Therapeutics, Inc.$40K
- Sobi, Inc$16K
- Pfizer$9K
- Bayer$7K
What the payments were for
- Consulting fees$9,42089%
- Speaking & faculty fees$7507%
- Food & beverage$3964%
- Education$591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 2 | $4,954 |
| Chiesi USA, Inc. | 5 | $4,616 |
| Agios Pharmaceuticals, Inc. | 2 | $809 |
| Sobi, Inc | 1 | $135 |
| Genetix Biotherapeutics Inc | 1 | $54 |
| Novo Nordisk | 2 | $42 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,625 in reported general payments places this provider in the 75th percentile of 42 pediatric hematology-oncology providers in Arizona.
See all pediatric hematology-oncology providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Deferasirox | 23 | $92,209 |
| EpogenEpoetin Alfa | 20 | $66,924 |
| Oxycodone Hcl | 11 | $179 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Mesa
- Naresh ReddivallaMesa$1K
- Misty VillarMesa$389
- Joseph TorkildsonMesa$338
- Xiaxin LiMesa$186
- Santosh HanmodMesa$135
- James WilliamsMesa$101
- Esteban AbellaMesa$26
- Dana SalzbergPhoenix$380K
- Holly MillerPhoenix$132K
- Natasha BalaPhoenix$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.